Trafalgar International (GCAN) Receivables - Net (2020 - 2021)
Greater Cannabis Company (GCAN) posted quarterly Receivables - Net of $36750.0 for Q3 2021, up 55.89% year-over-year from $23575.0 in Q3 2020, and little changed quarter-over-quarter from $36750.0 in Q2 2021.
Trafalgar International (GCAN) Receivables - Net (2020 - 2021) Analysis & Trends
Greater Cannabis Company's Receivables - Net history runs 2 years deep, the most recent figure standing at $36750.0 for Q3 2021.
- In Q3 2021, Receivables - Net rose 55.89% year-over-year to $36750.0; the TTM figure through Sep 2021 stood at $36750.0 (up 55.89% YoY), while the FY2020 annual figure was $36750.0, changed N/A from the prior year.
- Receivables - Net for Q3 2021 stood at $36750.0, roughly flat from $36750.0 in the prior quarter.
- The five-year high for Receivables - Net was $36750.0 in Q4 2020, with the low at $23575.0 in Q2 2020.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - |
| 10 | Trafalgar International | 236,233.75 | 236,233.75 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2021 | 36,750.00 |
| Sep 30, 2021 | 36,750.00 |
| Jun 30, 2021 | 36,750.00 |
| Jun 30, 2021 | 36,750.00 |
| Mar 31, 2021 | 36,750.00 |
| Mar 31, 2021 | 36,750.00 |
| Dec 31, 2020 | 36,750.00 |
| Dec 31, 2020 | 36,750.00 |
| Sep 30, 2020 | 23,575.00 |
| Sep 30, 2020 | 23,575.00 |
| Jun 30, 2020 | 23,575.00 |
| Jun 30, 2020 | 23,575.00 |